(EXPI) eXp World Holdings - Overview
Stock: Real Estate Brokerage, Cloud Platform, Virtual Office, Training Resources
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 2.08% |
| Yield on Cost 5y | 0.28% |
| Yield CAGR 5y | 25.74% |
| Payout Consistency | 99.2% |
| Payout Ratio | 616.7% |
| Risk 5d forecast | |
|---|---|
| Volatility | 54.9% |
| Relative Tail Risk | -10.2% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.32 |
| Alpha | -36.66 |
| Character TTM | |
|---|---|
| Beta | 1.028 |
| Beta Downside | 0.845 |
| Drawdowns 3y | |
|---|---|
| Max DD | 69.73% |
| CAGR/Max DD | -0.23 |
Description: EXPI eXp World Holdings January 15, 2026
eXp World Holdings, Inc. (NASDAQ: EXPI) operates a cloud-based real-estate brokerage platform that serves residential homeowners and buyers through three segments-North American Realty, International Realty, and Other Affiliated Services. The firm functions as a licensed broker for both residential and commercial transactions and supplements its core brokerage with technology (FrameVR.io), media (SUCCESS brand), and coworking services (SUCCESS Space).
As of FY 2023, eXp reported revenue of roughly $2.1 billion and a net operating income margin of about 12 %, driven by a rapid expansion of its agent network to over 100,000 licensed agents worldwide-a 30 % increase year-over-year. The company’s transaction volume exceeded $150 billion, reflecting its scalable, virtual-first model that reduces overhead compared with traditional brick-and-mortar brokerages.
The business benefits from macro-level trends such as persistent low housing inventory in key markets, heightened consumer demand for virtual property tours, and the broader digitization of real-estate services. These drivers support eXp’s cost-efficient, cloud-centric approach, which can capture market share from legacy brokerages that rely on physical office footprints.
For a deeper, data-driven valuation analysis, you might explore ValueRay’s platform.
Piotroski VR‑10 (Strict, 0-10) 2.5
| Net Income: -19.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.24 > 0.02 and ΔFCF/TA -23.32 > 1.0 |
| NWC/Revenue: 2.13% < 20% (prev 1.98%; Δ 0.15% < -1%) |
| CFO/TA 0.26 > 3% & CFO 118.5m > Net Income -19.3m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 1.45 > 1.5 & < 3 |
| Outstanding Shares: last quarter (160.8m) vs 12m ago 4.90% < -2% |
| Gross Margin: 7.14% > 18% (prev 0.08%; Δ 706.1% > 0.5%) |
| Asset Turnover: 1050 % > 50% (prev 1029 %; Δ 20.58% > 0%) |
| Interest Coverage Ratio: -5.71 > 6 (EBITDA TTM -5.03m / Interest Expense TTM 2.60m) |
Altman Z'' 0.01
| A: 0.22 (Total Current Assets 323.1m - Total Current Liabilities 223.5m) / Total Assets 458.7m |
| B: -0.22 (Retained Earnings -100.9m / Total Assets 458.7m) |
| C: -0.03 (EBIT TTM -14.8m / Avg Total Assets 445.7m) |
| D: -0.45 (Book Value of Equity -101.3m / Total Liabilities 223.5m) |
| Altman-Z'' Score: 0.01 = B |
Beneish M -3.14
| DSRI: 1.12 (Receivables 123.8m/105.1m, Revenue 4.68b/4.45b) |
| GMI: 1.05 (GM 7.14% / 7.51%) |
| AQI: 1.03 (AQ_t 0.26 / AQ_t-1 0.26) |
| SGI: 1.05 (Revenue 4.68b / 4.45b) |
| TATA: -0.30 (NI -19.3m - CFO 118.5m) / TA 458.7m) |
| Beneish M-Score: -3.14 (Cap -4..+1) = AA |
What is the price of EXPI shares?
Over the past week, the price has changed by -4.20%, over one month by -7.38%, over three months by -10.72% and over the past year by -20.34%.
Is EXPI a buy, sell or hold?
- StrongBuy: 1
- Buy: 0
- Hold: 1
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the EXPI price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 13 | 50.1% |
| Analysts Target Price | 13 | 50.1% |
| ValueRay Target Price | 7.9 | -8.5% |
EXPI Fundamental Data Overview February 03, 2026
P/B = 6.11
Revenue TTM = 4.68b USD
EBIT TTM = -14.8m USD
EBITDA TTM = -5.03m USD
Long Term Debt = unknown (none)
Short Term Debt = 14.0k USD (from shortTermDebt, two quarters ago)
Debt = 14.0k USD (from shortLongTermDebtTotal, two quarters ago)
Net Debt = -112.8m USD (from netDebt column, last quarter)
Enterprise Value = 1.32b USD (1.44b + Debt 14.0k - CCE 112.8m)
Interest Coverage Ratio = -5.71 (Ebit TTM -14.8m / Interest Expense TTM 2.60m)
EV/FCF = 12.22x (Enterprise Value 1.32b / FCF TTM 108.3m)
FCF Yield = 8.18% (FCF TTM 108.3m / Enterprise Value 1.32b)
FCF Margin = 2.31% (FCF TTM 108.3m / Revenue TTM 4.68b)
Net Margin = -0.41% (Net Income TTM -19.3m / Revenue TTM 4.68b)
Gross Margin = 7.14% ((Revenue TTM 4.68b - Cost of Revenue TTM 4.34b) / Revenue TTM)
Gross Margin QoQ = 6.55% (prev 7.08%)
Tobins Q-Ratio = 2.88 (Enterprise Value 1.32b / Total Assets 458.7m)
Interest Expense / Debt = 3843 % (Interest Expense 538.0k / Debt 14.0k)
Taxrate = 21.04% (932.0k / 4.43m)
NOPAT = -11.7m (EBIT -14.8m * (1 - 21.04%)) [loss with tax shield]
Current Ratio = 1.45 (Total Current Assets 323.1m / Total Current Liabilities 223.5m)
Debt / Equity = 0.00 (Debt 14.0k / totalStockholderEquity, last quarter 235.3m)
Debt / EBITDA = 22.44 (negative EBITDA) (Net Debt -112.8m / EBITDA -5.03m)
Debt / FCF = -1.04 (Net Debt -112.8m / FCF TTM 108.3m)
Total Stockholder Equity = 217.6m (last 4 quarters mean from totalStockholderEquity)
RoA = -4.34% (Net Income -19.3m / Total Assets 458.7m)
RoE = -8.88% (Net Income TTM -19.3m / Total Stockholder Equity 217.6m)
RoCE = -6.30% (EBIT -14.8m / Capital Employed (Total Assets 458.7m - Current Liab 223.5m))
RoIC = -5.38% (negative operating profit) (NOPAT -11.7m / Invested Capital 217.6m)
WACC = 9.70% (E(1.44b)/V(1.44b) * Re(9.70%) + (debt cost/tax rate unavailable))
Discount Rate = 9.70% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 2.26%
[DCF Debug] Terminal Value 69.73% ; FCFF base≈146.2m ; Y1≈128.8m ; Y5≈105.9m
Fair Price DCF = 9.81 (EV 1.45b - Net Debt -112.8m = Equity 1.56b / Shares 158.8m; r=9.70% [WACC]; 5y FCF grow -14.59% → 2.90% )
EPS Correlation: -33.03 | EPS CAGR: -8.80% | SUE: 0.0 | # QB: 0
Revenue Correlation: 18.25 | Revenue CAGR: 5.51% | SUE: 1.70 | # QB: 1
EPS next Quarter (2026-03-31): EPS=-0.01 | Chg30d=+0.010 | Revisions Net=+0 | Analysts=1
EPS next Year (2026-12-31): EPS=0.25 | Chg30d=+0.030 | Revisions Net=+1 | Growth EPS=+108.3% | Growth Revenue=+5.4%